SHORT REPORT

Ataxia, peripheral neuropathy, and anti-gliadin antibody. Guilt by association?

R J Lock, D S N A Pengiran Tengah, D J Unsworth, J J Ward, A J Wills


In 1996, Hadjivassiliou and co-workers made the intriguing observation that patients with a variety of cryptogenic neurological disorders including ataxia, neuropathy, myelopathy, and myopathy had a strikingly high (57%) prevalence of anti-gliadin antibodies (AGA). Some studies have supported these initial findings, but others reported AGA positivity in patients with idiopathic ataxia ranging from 0 to 19%. Hadjivassiliou et al subsequently found that the prevalence of AGA positivity in patients with familial ataxia was only 14% and Bushara and co-workers reported AGA positivity in 27% and 37% of patients with sporadic and autosomal dominant ataxias, respectively. Hadjivassiliou et al subsequently focused on patients with ataxia and AGA positivity, the majority of whom carried the HLA haplotype DQ2, coined the term “gluten ataxia”. This is a potentially important observation as it suggests that simple dietary manipulation (that is, gluten restriction) provides a potential treatment for a condition hitherto thought of as inexorably progressive.

All of these studies have been heavily reliant on AGA positivity as a screening tool and have inferred that the presence of these antibodies is synonymous with clinical gluten sensitivity. This is contested, as AGA are widely accepted to show poor specificity even for the prototypic gluten sensitive enteropathy. IgA autoantibodies including anti-endomysial (AEA) and anti-tissue transglutaminase (tTG) are highly specific and sensitive. We hypothesised that the presence of AGA in neurological cases was a non-specific finding. We therefore studied the prevalence of other common irrelevant food antibodies in these patients.

METHODS

Patients

Over a 2 year period we prospectively investigated all newly referred patients with idiopathic or cryptogenic ataxia (27) and peripheral neuropathy (32) attending specialist clinics at Queen’s Medical Centre, Nottingham and the Derbyshire Royal Infirmary. In these clinics we see 5400 new neurology referrals annually, from a background population of 2 million people. During this time we also saw 220 patients with neuropathy and 36 patients with ataxia where an underlying cause could be elucidated on routine investigation.

In the ataxic group demyelination, alcohol toxicity, prolonged use of anticonvulsant medication, and viral or paraneoplastic causes were excluded. None of the patients had evidence of multiple system atrophy type C. All the patients had an MRI of the brain and all were screened for Friedreich’s ataxia and SCA 1, 2, 3, 6, and 7. During our study seven patients were discovered to have either a strong family history of ataxia (three cases) or the presence of a known genetic defect (Friedreich’s ataxia, two cases; SCA 3, one case; SCA 6, one case). In the subsequent analysis, these were utilised as an internal disease control group (group 1), leaving 20 remaining cases with idiopathic ataxia (group 2). In the acquired peripheral neuropathy group (group 3), alcohol excess, drug toxicity, paraproteinaemia, systemic vasculitis, vitamin/nutritional deficiencies, and other general medical disorders (connective tissue disorders, diabetes, etc) were excluded by appropriate investigation. In all cases the diagnosis was confirmed electrophysiologically by using standard electromyographic criteria. Twenty four cases were axonal and eight demyelinating in nature. These served as an external aged matched disease control group for the ataxia patients.

All patients gave informed consent and the local Ethics Committees at Derby and Nottingham approved the study.

Antibody assays

AGA (IgG and IgA) and IgA tTG were detected by enzyme linked immunosorbent assay (ELISA), according to the manufacturers instructions (Orgentec Diagnostika, Mainz, Germany). Cut off values used were those given by the manufacturers.

Abbreviations: AEA, anti-endomysial antibodies; AGA, anti-gliadin antibodies; CD, coeliac disease; ELISA, enzyme linked immunosorbent assay; HLA, human leukocyte antigen; OD, optical density; PCR-SSP, polymerase chain reaction using sequence specific primers; tTG, anti-tissue transglutaminase antibodies
manufacturer (anti-gliadin IgG<12 U/ml, anti-gliadin IgA<12 U/ml, and IGT<10 U/ml).

For other food antigen ELISAs, 100 μl volumes of cow’s milk β lactoglobulin or chicken ovalbumin (Sigma, Poole, UK) at 20 μg/ml in carbonate/bicarbonate buffer were used to coat the plates overnight at 4°C. All further incubations used 100 μl volumes, at room temperature, for 1 h. All wash steps used 0.05% Tween/PBS repeated three times. After washing, patient’s serum diluted to 1/50 in 0.05% Tween/PBS was applied to duplicate wells. After a further wash, 100 μl of either alkaline phosphatase conjugated goat anti-human IgA (Dako, Ely, UK) diluted 1 in 500 or alkaline phosphatase conjugated goat anti-human IgG (Dako) diluted 1 in 500 in 0.05% Tween/PBS was added to each well. Sigma 104 substrate was used according to the manufacturer’s instructions, and the optical density (OD) read at 405 nm. Cut-offs for in house ELISA assays, expressed as OD, were determined by the technique of probability plotting, as previously described.19 Typically, cut off values were anti-lactoglobulin IgA OD>0.05 U, anti-lactoglobulin IgG OD>0.25 U, anti-ovalbumin IgA OD>0.05 U, and anti-ovalbumin IgG OD>0.20 U.

Appropriate positive and negative control sera were included in all ELISA assays.

Class II antigens
DNA was extracted using the Whatman Bioscience Genomic DNA Purification System (Whatman, Brentford, UK) according to the manufacturer’s instructions. HLA-DR polymerase chain reaction using sequence specific primers (PCR-SSP) was adapted from Olerup and Zetterquist.11 HLA DQ PCR-SSP was adapted from Olerup et al.12 PCR-SSP samples were subjected sequentially to five cycles of PCR (96°C for 25 s, 70°C for 45 s, 72°C for 45 s), 22 cycles (96°C for 25 s, 65°C for 50 s, 72°C for 45 s), and four cycles (96°C for 25 s, 55°C for 60 s, 72°C for 120 s). PCR-SSP products were electrophoresed through a 1.5% agarose gel at 300 V for 20 min.

Statistics
Data were analysed using the binomial test (which formally tests for a difference between the proportion of categories in a sample against a hypothesised proportion, in this case the test population and reference data), ANOVA, or Fisher’s exact test, as appropriate (Analyse-it for Microsoft Excel version 1.62, Analyse-it Software, Leeds UK).

RESULTS
Table 1 shows the mean age, age range, male to female ratio, and antibody/HLA status for the three groups. Groups 2 and 3 were not significantly different in mean age (p = 0.111) or gender distribution (p = 0.308), Group 1, found incidentally during the study, is very small and statistical analysis was considered inappropriate. The data do illustrate, however, that food antibodies of all types are also found in hereditary ataxia. A high prevalence of IgG antibodies in particular was noted, ranging from 15% to 30% in the idiopathic groups. Regarding IgA anti-IGTG, no positive results were found.

DISCUSSION
We found a striking absence of serological evidence for occult CD in our cases. No case was positive for IgA anti-IGTG. This is very different to the reports of other groups of 12.5–25% frequency of CD in idiopathic ataxia.1 14 16 although a lower prevalence of biopsy proven CD (2%) has been reported by one group.18 By contrast, food antibodies (wheat gliadin, hen’s egg albumen, cow’s milk lactoglobulin), particularly of IgG type, were common in patients with idiopathic peripheral neuropathy or ataxia. These data support and extend the findings of Abele et al showing a non-significant increase in AGA in ataxia.19 This might simply reflect an age related phenomenon or it may imply a general heightened responsiveness of the gut immune system in these individuals or some problem with gut permeability or inflammation.

Again in contrast to the findings of others, we found no over representation of HLA DQ2 or HLA DQ8 in our cases.6 14 In other defined gluten sensitive disorders (CD, dermatitis herpetiformis), HLA DQ2 or HLA DQ8 is found in >95% of cases.20 21 Furthermore, in our study patients with the HLA DQ2 haplotype were no more likely to have AGA than those without (data not shown; p = 0.606).

Of note, we found very few patients who meet the inclusion requirements of Hadjivassiliou et al for “gluten ataxia”. Whereas they describe a group of 28 patients with idiopathic ataxia in 4 years who had AGA, 23 of whom were also HLA DQ2 positive,7 we have only four patients in 2 years who meet their criteria, that is, only one third of the incidence assuming that the Neuroscience Centres in Nottingham and Sheffield serve a similar sized population. We cannot rule out ascertainment bias as a contributing factor to the differences in the two sets of data.

Our results raise a number of interesting issues with regard to the nosological status of “gluten ataxia”. We disagree with the notion that AGA seropositivity per se is synonymous with gluten sensitivity either in neurological or other patient populations. Of our patients, 40% have AGA, within which must be contained the 10–15% of healthy individuals who also have AGA. Of these which have so called “gluten ataxia”? It is important to note that a similar percentage of patients with Huntington’s disease also have AGA.22 Even in the classical or prototypic gluten sensitive diseases (CD and dermatitis herpetiformis), these antibodies lack specificity and alternative antibody disease markers (IgA anti-ITG, AEA) are utilised.7 An analogous situation arises with IgE class antibodies that may be detected in persons without any allergic symptoms and which in some cases disappear with time.21

Whether AGA positivity mirrors, via immune mediated mechanisms, gluten induced neurological damage is...
disputed. We contend that AGA in hereditary ataxias must be an epiphenomenon.

Our study has two major weaknesses. We did not capture all the neuropathy and ataxia cases from the background population as patients may have been referred to other hospitals in the region or not referred at all as the diagnosis was obvious (for example, diabetic neuropathy). In addition, in common with most other previous studies we have been unable to obtain antibody prevalence data on an aged matched control group (this is planned as a future study). For comparison, however, data exist for healthy younger adults, including blood donor populations, showing IgG antibodies to foods to be common. Our own (unpublished) data (blood donors, n = 30 (15 male), median age 40) show AGA in five (17%), anti-ovalbumin in seven (23%), and anti-lactoglobulin in three (10%).

The most appealing aspect of the "gluten ataxia" hypothesis is that it offers the prospect of an exclusion diet as a realistic therapeutic possibility. This non-blind study needs confirmation from other centres. Our data so far do not support the view that idiopathic ataxia is a gluten related disorder. This would appear to be a case of guilt by association based on the finding of a non-specific serological marker (AGA).

Authors' affiliations

R J Lock, D J Unsworth, J J Ward, Immunology and Immunogenetics, North Bristol NHS Trust, Southmead Hospital, Bristol, UK
D S N A Pengiran Tengah, A J Wills, Department of Neurology, Queen's Medical Centre, Nottingham, UK
This study was funded by the Stanhope Trust, Derbyshire Royal Infirmary, the Showering Fund, North Bristol NHS Trust, and the ImmunoLogy Research Fund, North Bristol NHS Trust. The funding sources had no role in study design, in the collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the paper for publication.

Competing interests: none declared

Correspondence to: Dr A J Wills, Department of Neurology, Queen's Medical Centre, Nottingham, UK; adewills61@hotmail.com

Received 9 November 2004
Revised version received 1 February 2005
Accepted 7 March 2005

REFERENCES


